Aurobindo Pharma on Friday said the US health regulator has issued a warning letter to a formulation manufacturing facility of its arm, Eugia Pharma Specialities Ltd, in Telangana.<\/p>\n
In May this year the company had stated that the US Food and Drug Administration (USFDA) inspected Unit-I, a formulation manufacturing facility of Eugia Pharma Specialities Ltd located at Telangana from February 16 to February 27, 2026.<\/p>\n
The inspection had concluded with four observations and the USFDA had determined the facility as 'official action indicated' (OAI).<\/p>\n
"Subsequent to OAI, the unit has received a warning letter," Aurobindo Pharma said in a regulatory filing.<\/p>\n
There is no impact on the existing supplies to the US markets, it added.<\/p>\n
The company further said the Unit I of Eugia Pharma Specialities Ltd, is contributing to about 2 per cent to company's overall group revenue.<\/p>\n
Aurobindo Pharma said it remains committed to working closely with the US FDA and continues to enhance its compliance on an ongoing basis.<\/p>\n
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)<\/p>\n
Don't miss the most important news and views of the day. Get them on our Telegram channel<\/p>\n
First Published: Aug 14 2026 | 1:44 PM IST<\/p>\n